<DOC>
	<DOCNO>NCT00820456</DOCNO>
	<brief_summary>The objective study include : - Testing unique way image people colorectal cancer cancer spread liver use magnetic resonance imaging ( MRI ) ; - Seeing MRI process use across multiple imaging platform ; - Determining whether result image reproduce ; - Reviewing MRI result relate cancer response combination therapy clinical endpoint .</brief_summary>
	<brief_title>Metastatic Colorectal Cancer : Treatment Response With Dynamic Contrast MRI</brief_title>
	<detailed_description>This study investigate use projection reconstruction dynamic contrast-enhanced MRI ( DCE-MRI ) surrogate marker tumor vascularity patient treat antiangiogenic agent bevacizumab . DCE-MRI gain popularity method assess functional response tumor agent target vascular endothelial growth factor ( VGEF ) pathways . DCE-MRI measurement propose non-invasive measure tumor biologic activity ( case antivascular therapy ) early response treatment . A number phase I II study demonstrate ability DCE-MRI detect perfusion change associate tumor biologic response vascularly target agent . It suggest pre-treatment DCE-MRI might identify tumor high intrinsic perfusion tumor likely respond antivascular-based therapy . However , current use DCE-MRI clinical setting challenge . Trade-offs spatial coverage , time , spatial resolution make technique difficult implement human study may limit reliability . The use projection reconstruction-based acquisition mitigate need trade-off simultaneously provide high temporal spatial resolution data DCE-MRI analysis .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Arm A : Participants must &gt; 18 year old ; Participants must ECOG performance status 01 ; Participants must pregnant breastfeeding ; Participants must prior histological documentation adenocarcinoma colon rectum ; Participants must commence chemotherapy FOLFOX plus bevacizumab ; Participants must prior exposure bevacizumab . Prior systemic chemotherapy agent allow . The last dose systemic chemotherapy must &gt; 3 month prior study entry ; Participants prior radiotherapy prior local therapy liver ( radioablation therapy , chemoembolic therapy ) acceptable . They must least 4 week past last administration therapy ; Participants must least 4 week past major surgery , include surgery liver ; Participants prior malignancy colon cancer allow , provide treat curative intent , evidence recurrence malignancy ; Participants must life expectancy great 3 month ; Participants must ability understand willingness sign write informed consent form . Arm B : Inclusion Criteria Participants must &gt; 18 year old ; Participants must ECOG performance status 01 ; Participants must pregnant breastfeeding ; Participants must prior histological documentation type cancer metastasis liver ( see Imaging Criteria ) ; Participants must project within stable treatment condition prior scan ( see section 4.3 definition stable treatment condition ) ; Participants must least 4 week past major surgery , include surgery liver ; Participants must life expectancy great 3 month ; Participants must ability understand willingness sign write informed consent form . Imaging Criteria : Participants must least one hepatic lesion great equal 3 cm maximal diameter cross sectional imaging study ( CT MRI ) perform within 4 week prior study enrollment ; Participants must least one qualify liver lesion ( i.e . one great equal 3 cm ) confirm metastatic adenocarcinoma colon rectum base one follow criterion : Histologic ( FNA core biopsy ) proof malignancy compatible metastasis colorectal carcinoma ; OR Demonstration image feature tumor metastasis liver , include least one following : 1. evidence heterogeneous enhancement central tumor necrosis CT MRI ; 2. previously demonstrate interval enlargement lesion &gt; 25 % long diameter ; 3 . PET image demonstrate metabolic activity characteristic malignancy ( FDG uptake great background liver ) . For participant undergone local hepatic surgical , radiation , ablative , embolic therapy , date qualify image study ( y ) qualify biopsy must least 30 day last instance local therapy . Furthermore , crosssectional imaging perform least 30 day local therapy must demonstrate area residual viable tumor ( judged enhance tissue follow contrast administration ) long diameter â‰¥ 3cm least one crosssectional axis . Arms A B ( Unless Otherwise Indicated ) : Patients contraindication MRI , include : 1 . Contraindicated metallic device , include pacemaker , nonMRI compatible aneurysm clip , nonMRI compatible mechanical and/or electrical device , metallic fragment ; 2 . Patients severe claustrophobia ( patient milder form claustrophobia successfully allay oral anxiolytic therapy allow ) ; Patients contraindication gadolinium , include : ) Hypersensitivity gadoliniumcontaining MR contrast agent ; Severe impair renal function estimate glomerular filtration rate &lt; 30 mL/min/1.73 m2 and/or dialysis ; Patients severely compromise pulmonary , cardiovascular , mental status . Patients must severe congestive heart failure ( defined New York Heart Association Class II great ) ; For Arm A : Any major medical illness , investigator 's opinion , would : ( 1 ) prevent administration completion institution 's standard care FOLFOX/bevacizumab therapy ; ( 2 ) prevent administration completion protocolspecified imaging ; and/or ( 3 ) interfere followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>colorectal neoplasm</keyword>
	<keyword>colorectal neoplasm</keyword>
	<keyword>metastasis</keyword>
	<keyword>metastasis</keyword>
	<keyword>liver</keyword>
	<keyword>hepatic metastasis</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>perfusion image</keyword>
	<keyword>MRI</keyword>
	<keyword>magnetic resonance imaging</keyword>
	<keyword>dynamic contrast enhance MRI</keyword>
	<keyword>dynamic contrast enhance magnetic resonance imaging</keyword>
</DOC>